Pharmacy & Medication Management
Expert articles and analysis related to pharmacy & medication management.
AI Summary — Last 24 Hours
A D.C. Circuit ruling revived part of Teva’s challenge to Medicare drug price negotiation as Austedo faces IRA-related price cuts, keeping legal uncertainty alive around CMS’ Part D affordability strategy and the drug-pricing assumptions embedded in MA, ACO REACH, and medication-adherence economics (Endpoints News). At the delivery and payer level, infliximab switching patterns and Optum Rx’s PBM “reinvention” push underscore a near-term VBC tension: sponsors and providers are trying to capture biosimilar/formulary savings while avoiding disruption in specialty-drug adherence, site-of-care management, and total-cost-of-care contracts (AJMC).
Related Articles
Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom
After a lower court rejected Teva's case last fall, a federal appeals court has revived part of the drugmaker’s lawsuit against Medicare negotiations. The DC Circuit Court ruled on Tuesday that Teva...
Nationwide Trends and Cost Implications of Switching Between Infliximab Products
AI In Pharmacovigilance: The Commercial and Market-Access Imperative
Heidi Overton nominated for FDA commissioner - aha.org
Heidi Overton nominated for FDA commissioner  aha.org
Trump nominates policy aide Overton to lead FDA
Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.
Amylin design debate heats up as Lilly's crucial mid-stage weight loss data near
In the amylin race, drug design appears to be a key differentiator. Later this year, Novo Nordisk’s CagriSema is likely to become the first approved drug containing an amylin analog and a GLP-1 agoni...
Why a supplement supply chain hides behind its label
Why a supplement supply chain hides behind its label  KevinMD.com
How JAK Inhibitors Are Reshaping Vitiligo Treatment Goals
Trump to pick Heidi Overton to lead the FDA
President Donald Trump is expected to nominate Heidi Overton to be the next FDA commissioner, according to a source familiar with the decision, setting a new chapter for the drug agency three ...
Why doctors won’t prescribe opioids, and who profits
Why doctors won’t prescribe opioids, and who profits  KevinMD.com